Risk of diabetic ketoacidosis associated with the use of sodium-glucose cotransporter-2 inhibitors

Diabetic Ketoacidosis (DKA) has been reported in patients with diabetes taking SGLT-2 inhibitor drugs both in clinical trials and in real life situations, particularly amongst patients taking insulin. The US Food and Drug Administration (FDA) has issued a safety communication following 20 cases of DKA in patients receiving these drugs.1 This concern has also prompted an American Association of Clinical Endocrinologists and American College of Endocrinology position statement covering the use of SGLT-2 inhibitors in people with type 2 diabetes.2 This report provides the ABCD position on this issue.